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by Dutch Patients With Lung or Colorectal
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Linda Brom, PhD3, Bregje D. Onwuteaka-Philipsen, PhD2,
Gert P. Westert, PhD1, and A. Stef Groenewoud, PhD1
Abstract
Understanding the overuse and underuse of health-care services in the end-of-life (EoL) phase for patients with lung cancer (LC)
and colorectal cancer (CRC) is important, but knowledge is limited. To help identify inappropriate care, we present the health-
care utilization profiles for hospital care at the EoL of patients with LC (N ¼ 25 553) and CRC (N ¼ 14 911) in the Netherlands
between 2013 and 2015. An administrative database containing all in-hospital health-care activities was analyzed to investigate the
association between the number of days patients spent in the emergency department (ED) or intensive care unit (ICU) and their
exposure to chemotherapy or radiotherapy. Fewer patients received hospital care as death neared, but their intensity of care
increased. In the last month of life, the average numbers of hospital bed days, ICU days, and ER contacts were 9.0, 5.5, and 1.2 for
patients with CRC, and 8.9, 6.2 and 1.2 for patients with LC in 2015. On the other hand, the occurrence of palliative consultations
ranged from 1% to 4%. Patients receiving chemotherapy 6 months before death spent fewer days in ICU than those who did not
receive this treatment (odds ratios: CRC ¼ 0.6 [95% confidence interval: 0.4-0.8] and LC ¼ 0.7 [0.5-0.9]), while those receiving
chemotherapy 1 month before death had more ED visits (odds ratios: CRC ¼ 17.2 [11.8-25.0] and LC ¼ 15.8 [12.0-20.9]). Our
results showed that patients who were still receiving hospital care when death was near had a high intensity of care, yet palliative
consultations were low. Receiving chemotherapy or radiotherapy in the final month of life was significantly associated with more
ED and ICU contacts in patients with LC.
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Introduction
Lung cancer (LC) and colorectal cancer (CRC) are 2 of the 5
most common types of cancer in the Netherlands,1 with 12 600
and 15 000 new patients, respectively, diagnosed in 2015. With
5-year survival rates of 18% (LC) and 58% (CRC), survival is
low.1 Furthermore, patients with LC and CRC have the second
and third highest hospital care costs of all patients with cancer.2
Due to screening programs, more patients with cancer are
identified at earlier disease stages. Cancer is increasingly
becoming a chronic disease as a result of new chemotherapies
and targeted therapies, meaning that the end-of-life (EoL)
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phase and the process of dying are longer and more gradual.
The early detection of the palliative phase, advance care plan-
ning (ACP), and well-considered EoL care are therefore
becoming increasingly important; however, we know that med-
ical care can be both overused and underused.3 It can be over-
used in patients with cancer who receive aggressive treatments
during the EoL phase, which increases their burden while
decreasing their quality of life.4,5 The underuse of health care,
for instance not having timely EoL discussions, is associated
with higher costs and a lower quality of death and dying.6
Analyzing the health-care utilization (HCU) of a patient
group forms the first crucial step toward improving their health
care and is a tool for the identification of the overuse and
underuse of medical care. Here, we aim to present the HCU
profiles (HCUP) of patients with LC and CRC using activity-
based hospital data. This will provide complementary and con-
trasting information to the analysis of diagnosis-related group
(DRG)–based hospital data, which was previously performed
by Bekelman et al.7
Materials and Methods
Study Population and Selection
This population-based cohort study includes insured Dutch per-
sons (99% of the Dutch population)8 who died in 2013, 2014, or
2015 with a diagnosis of LC and/or CRC for whom hospital
medical care had been registered. The patients were included as
patients with LC if they had been diagnosed with non-small-cell
lung carcinoma or small-cell lung cancer, neoplasm bronchus
lung, or small- and large-cell bronchus carcinoma. Patients with
CRC were included if they had been diagnosed with colorectal
malignancyormalignant neoplasmof the colon. Patients under 18
at the time of death or those who lacked a valid citizen service
number and post code were excluded from the analysis.
Data
A national database of administrative hospital data at the
health-care activity level was used in the analyses presented
here. These activities are registered by all Dutch hospitals (8
academic and 92 general hospitals) and by more than 300 inde-
pendent treatment centers. The data also contained information
regarding the institution providing the care as well as the age
and gender of the patients. For 2013 and 2014, the data covered
95% of the delivered and billable care. For 2015, this was
approximately 70% due to the administrative delay in registries
after care had been given.
Expert Panel
Five medical experts were involved: 2 pulmonologists/oncolo-
gists and 3 experts specializing in internal medicine and oncol-
ogy. All were specialized in palliative medicine. First,
individual in-depth interviews were conducted with 4 experts
using an interview guide to gain insights into their current
practice and the background and reasons for the HCU patterns
of Dutch patients with CRC or LC in the EoL phase. During the
analysis phase, the experts classified each health-care activity
into meaningful clusters (Table 1) and compared the volume
and intensity of EoL HCU to their experiences of daily prac-
tice. Also, the experts indicated which types of care had been
registered too frequently in their opinion and what would be
potential areas for improvement. Finally, the experts argued
that unplanned and unwanted admissions such as ED contacts
and days in ICU were important to investigate further. They
formulated an additional question regarding the association
between unwanted admissions and chemotherapy and radio-
therapy. It was not possible to identify avoidable or unwanted
hospital bed days from the available data; therefore, this study
was focused on ICU days and ED contacts.
Clustering Health-Care Activities
More than 13 000 different health-care activities were included
in the database, many of which can be grouped together. The
experts were therefore asked to define the important and rele-
vant health-care clusters for the EoL phases of patients with
CRC and LC separately; it was not necessary to identify the
same categories for the 2 illnesses. Subsequently, 2 teams of
experts appointed the 75% most frequently occurring health-
care activities within each specialism to one of these cate-
gories. The process of defining the categories was iterative,
meaning that within and between the 2 teams, the categories
were adjusted and refined during the clustering process until a
consensus was reached. One of the experts checked and fina-
lized the clustering. The health-care activity codes for which no
description was available (<1%) and the additional costs for
Key Points
Questions
What is the hospital health-care utilization of Dutch
patients with lung cancer (LC) and colorectal cancer
(CRC) in the end of life?
Findings
We found that, for patients still receiving hospital care
when death neared, the intensity of hospital care was high,
yet palliative consultations were low. During the last
month of life, chemotherapy and radiotherapy were signif-
icantly associated with more emergency department and
intensive care unit visits in patients with LC.
Conclusion
Palliative care is potentially underused in the end-of-life
phase. Medical specialists should consider the intensity
of treatments when discussing them with patients.
Advance care planning can play a substantial role in this.
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laboratory work, ICU admissions, house visits, or travel
expenses were excluded because HCU, not health-care costs,
were the focus of this investigation. Also, postmortem exam-
inations were excluded from the clustering as these were not
part of the EoL HCU.9
Analyses
The intensity of the HCU was examined by calculating the
percentage of patients who received care described within the
clusters and determining how often these care activities were
performed on average per patient per month in the last 6, 3, and
1 month(s) before death. The associations between radiother-
apy or chemotherapy and ICU days or ED contacts were also
analyzed using a 2  2 frequency table, for which the corre-
sponding odds ratios (OR) and 95% confidence intervals (CI)
were calculated. The analyses were performed using SAS
Enterprise Guide 9.2.
Results
Patient Characteristics
The characteristics of the 25 533 patients with CRC and 14 911
patients with LC included in this study are presented in Table 2.
Table 1. Clusters of Health-Care Activities and Descriptions.
Category Description
Inpatient days
Hospital bed wlays A first or subsequent clinical admission, classes A, B, and C
ICU days Low, medium, and high care in the ICU
Outpatient days
ED visit Life support in the ED
Ambulatory visit A first or return visit
Specialty care consultations
Palliative care consultation Specific health-care activity describing a palliative consultation
Multidisciplinary consultation Co-treatments with other specialists, (clinical) multidisciplinary consultation and activities
Consultation Consultations between patient and specialist, face-to-face or by telephone
Allied and therapeutic care, per 15 minutes All allied care and consultations, including physiotherapists, nutritionists, nurse practitioners,
psychologists, social workers, optometrists, and geriatric rehabilitation
Diagnostic tests
Laboratory test All lab tests regarding hematology and small chemistry
Noninvasive diagnostic test—pathological Microbiological, histological and pathological (laboratory) tests
Other noninvasive diagnostics CGA, spirograph tests, interpreting radiology results, preassessments, blood pressure
measurement, audiometric tests, and so on
Invasive diagnostics Includes colonoscopies and bronchoscopies, as well as biopsies and diagnostic punctures
Imaging
Conventional radiology Ultrasounds and X-rays, Doppler, duplex, EEG
CT scan CT scans
MRI scan MRI scans
PET scan PET scans
Nuclear scan other than PET SPECT and radioactive isotope tests
Procedures and treatments
Chemotherapy Includes therapies as cisplatin, oxaliplatin, gemcitabin, docetaxel, and irinotecan
CRC/LC surgery Surgeries registered under diagnosis codes specified in Table 1a and 1b, including tumor
resection, tracheotomy, and therapeutic biopsies
Non-CRC/LC surgery Surgeries other than the aforementioned, for instance, heart transplants; hip replacements,
cataract, and hernia surgeries; and resections, reconstructions, and therapeutic biopsies
Biologics Includes therapies such as bevacizumab, rituximab, and gefitinib
Radiotherapy Radiation and radiotherapy fractions.
Other (care and items) Pre- and post-surgery/chemotherapy/radiotherapy care, dental work, devices and implants
(pacemaker, Steffeeplate, shunt), prosthetics, dialysis, injections, catheters, and so on
Abbreviations: CGA, comprehensive geriatric assessment; CRC, colorectal cancer; CT, computed tomography; ED, emergency department; EEG, electroence-
phalogram; ICU, intensive care unit; LC, lung cancer; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, single photon computed
tomography.
Table 2. Baseline Characteristics of All Patients with Lung or Color-
ectal Cancer who Died, 2013 to 2015.
Lung Cancer,
N ¼ 25 533
Colorectal Cancer,
N ¼ 14 911
Total
Gender, %
Male 15 324 (60.0%) 8494 (56.5%)
Female 10 209 (40%) 6417 (43.5%)
Mean age at death
Male 70.6 71.6
Female 67.1 72.1
de Man et al 3
For both CRC and LC, more males than females passed away in
the years 2013 to 2015.
Health-Care Utilization Profiles
The main clusters of health-care activities for patients with
CRC and LC are presented in Table 1, while Table 3 shows
the HCUP for these patients by cluster over 3 different time
periods: 6 months, 3 months, and 1 month before death. It
displays the proportion of patients who received a certain type
of care and the average number of times they received it each
month. In all 3 years, the 3 most frequently registered health-
care activities for patients with both CRC and LC during the
EoL phase were ambulatory visits, laboratory tests, and con-
ventional radiology. Overall, the number of patients receiving
hospital care decreased as their death neared, although the
intensity of care per month increased for those still receiving it.
In 2015, during their last 6 months of life, 55.2% of patients
with CRC and 57.2% of patients with LC were admitted to
hospital (not including ICU and ER admissions). In the last
month of life, these proportions decreased to 18.9% and
21.4%, respectively, with an average stay of 9 hospital bed
days. For patients who visited the ICU (2%-3%) and the ED
(13%-16%) during their last month of life, the numbers of
ICU days and ED contacts during this period were 5.5 days
and 1.2 times, respectively, for patients with CRC and 6.2 days
and 1.2 times for patients with LC.
Less than 2% of all patients had a palliative care team con-
sultation in their last month of life (Table 3), while up to 20% of
the patients with CRC and 23% of the patients with LC had a
(multidisciplinary) consultation with their health-care special-
ist in this timeframe.
During the last 6 months of life, up to 66% of the patients
with CRC and 79% of the patients with LC underwent conven-
tional radiology. A total of 56% to 64% of patients with CRC
and 61% to 66% for patients with LC received a computed
tomography (CT) scan during this period, which dropped to
10% to 14% for CRC and 12% to 16% for LC during the last
month of the patient’s life.
During their last 6 months of life, a small number of patients
received cancer-related surgery, representing 9% of the
patients with CRC and 1% of the patients with LC. No more
than 1% of patients with LC received biologics, although 13%
to 15% of patients with CRC received these treatments
throughout the whole EoL phase. The opposite was true for
radiotherapy, as up to 31% of the patients with LC received
this treatment compared to just 13% of patients with CRC in
the last 6 months of life. Overall, in the last month of life, we
found that a very low percentage of patients underwent cancer-
specific treatments and procedures.
Association Between Chemotherapy/Radiotherapy
and ED Contacts
Patients with CRC receiving chemotherapy had more ED con-
tacts during their last 6 months before death than patients who
did not undergo chemotherapy during this period (unadjusted
odds ratio [OR] ¼ 1.8, 95% confidence interval [CI]¼ 1.6-2.1;
Table 4). During the last month of life, the OR increased to 17.2
(95% CI ¼ 11.8-25.0). We observed a similar increase in
patients with LC (OR ¼ 2.0 six months before death, 95%
CI ¼ 1.8-2.2; OR ¼ 15.8 one month before death, 95% CI ¼
12.0-20.9). Patients with both CRC and LC receiving radio-
therapy in their last month of life were significantly more fre-
quently admitted to the ED than patients who did not undergo
radiotherapy (OR for patients with CRC ¼ 4.6, 95% CI ¼ 2.6-
8.1; OR for patients with LC ¼ 4.2, 95% CI ¼ 3.2-5.4).
Association Between Chemotherapy/Radiotherapy
and ICU Contacts
Patients receiving chemotherapy 6 months before their death
spent fewer days in the ICU than patients who did not undergo
this treatment. We observed that, in the last month of life,
patients with LC undergoing chemotherapy were admitted
to the ICU (OR ¼ 2.9, 95% CI ¼ 1.6-5.2) more often than
those who did not receive chemotherapy during this period.
Patients with LC receiving radiotherapy in their last month of
life were significantly more frequently admitted to the ICU
than patients who did not undergo this treatment (OR ¼ 2.7,
95% CI: ¼ 1.3-5.6).
Discussion
We revealed that a substantial number of patients with LC and
CRC received highly intensive treatments during their EoL
phase. Receiving chemotherapy or radiotherapy in the last
month of life was found to be strongly associated with
increased ER and ICU contacts in patients with LC.
Our results regarding hospital admissions are comparable to
those of Bekelman et al who reported that 7% of elderly Dutch
patients who died of cancer in 2010 spent 1 or more day(s) in
ICU during their last 30 days of life, while 42% were hospita-
lized in an acute-care hospital.7 They also found that ICU
admissions were more than twice as common in the United
States than in the other 6 reporting countries for patients with
cancer, including the Netherlands. Teno et al reported that
29.2% of all (Medicare-supported) patients with cancer in the
United States were admitted to the ICU during their last
30 days of life (data from 2009).10 These findings were sub-
stantially higher than those of the present study (3% to 5%);
however, the Netherlands has one of the lowest rates of ICU
admissions among the 8 countries investigated by Teno et al.10
Although these findings show that HCU during the EoL phase
is lower in the Netherlands than in other countries, overuse (or
underuse) could still be present.
The medical experts included in this study indicated that the
HCUPs we identified corresponded with their experience of
daily oncological practice, describing them as “shockingly
intense.” According to them, the potential areas for improve-
ment in EoL care are to reduce the high number of admissions
to the ICU and ER, to reduce the number of patients receiving a
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CT scan and the overall number of scans each patient receives,
and to increase the number of palliative care consultations held
with patients. We will discuss each of these themes and their
level of appropriateness below.
Unwanted hospital admissions may be necessitated by a pro-
longed treatment during the EoL phase, as doctors may find it
difficult to cease high-impact treatments such as chemotherapy
and biological treatment in a timely manner11 and might not
always discuss preferences and treatment aims with the patient.12
Weargue that unplanned and even unwanted admissions could be
prevented by timely discussions regarding EoL care or ACP.
Palliative care consultations are ameans of giving patients amore
central role in their health care and the medical decisions sur-
rounding their EoL.13 AlthoughACP has its pros and cons, recent
studies have shown that ACP is able to improve the overall com-
pliance with patient EoL wishes and improve the satisfaction of
the patients and their families. It also reduces family stress, anxi-
ety, and depression,14-16 while increasing the quality of life and
survival rates in comparison to standard care16 and significantly
lowering health-care costs.6,17 Despite these benefits, there is
currently little evidence to indicate whether palliative care inter-
ventions implemented in the hospital, home, or outpatient clinic
are more effective than standard care practices at reducing ED
visits among patients with cancer during their EoL phase.18
Unfortunately, the number of patients receiving palliative
care consultations in our study was exceptionally low. One
explanation for this might be that, in the Dutch health-care
system, the DRG data on palliative consultations are only reg-
istered as palliative care when a multidisciplinary team is
actively providing palliative care, there has been at least 1
clinical or ambulant consultation, and the patient is solely
receiving palliative care with no other curative treatments. A
palliative consultation can be registered as a health-care activ-
ity; however, when the activity is not registered as palliative
care, it is not sent to the database we used for our analyses.
Although the number of palliative teams in Dutch hospitals is
increasing,19 supportive care specialists are only involved in
the care of 12% of non-sudden-death patients during their last
month of life.20 Also, other reported data suggest that 20% to
25% of a representative sample of Dutch patients with CRC
and LC had a palliative treatment aim in the 3 months before
their deaths as recorded by their general practitioners (GPs).21
The percentage of patients who receive palliative consultations
and the total number of these consultations might therefore be
higher than our results suggest, although they are still likely to
be relatively uncommon.
Our results suggest that high-impact treatments are associ-
ated with an increase in both days spent in the ICU in the last
month of life for patients with LC and the number of ED con-
tacts made throughout the entire EoL phase for both patients
with LC and CRC. We cannot conclude that these treatments
are inappropriate in the EoL phase on the basis of this study,
Table 4. Number of Patients With ED Contacts or ICU Days and the Number of Patients who Underwent Radiotherapy or Chemotherapy in
2015.
Chemotherapy,
N (%)
No
chemotherapy, %
Crude OR
[95%CI]
Radiotherapy,
%
No radiotherapy,
%
Crude OR
[95%CI]
Colorectal cancer (N ¼ 4123) N ¼ 1127 N ¼ 2996 N ¼ 396 N ¼ 3727
Last 6 months of life
1 ED-contact 610 (54.1) 1174 (39.2) 1 183 (46.2) 1603 (43.0) 1
No ED-contact 517 (45.9) 1822 (60.8) 1.8 [1.6-2.1] 213 (53.8) 2124 (57.0) 1.1 [0.9-1.4]
1 ICU-day(s) 44 (3.9) 204 (6.8) 1 23 (5.8) 227 (6.1) 1
No ICU-day 1083 (96.1) 2792 (93.2) 0.6 [0.4-0.8] 373 (94.2) 3500 (93.9) 1.0 [0.6-1.5]
N ¼ 136 N ¼ 3987 N ¼ 50 N ¼ 4073
Last month of life
1 ED-contact 93 (68.4) 447 (11.2) 1 20 (40.0) 517 (12.7) 1
No ED-contact 43 (31.6) 3540 (88.8) 17.2 [11.8-25.0] 30 (60.0) 3556 (87.3) 4.6 [2.6-8.1]
1 ICU-day(s) 6 (4.4) 116 (2.9) 1 3 (6.0) 118 (2.9) 1
No ICU-day 130 (95.6) 3871 (97.1) 1.5 [0.7-5.6] 47 (94.0) 3955 (97.1) 2.1 [0.7-6.9]
Lung cancer (N ¼ 6643) N ¼ 1969 N ¼ 4674 N ¼ 1420 N ¼ 5223
Last 6 months of life
1 ED-contact 1158 (58.8) 1963 (42.0) 1 728 (51.3) 2397 (45.8) 1
No ED-contact 811 (41.2) 2711 (58.0) 2.0 [1.8-2.2] 692 (48.7) 2836 (54.2) 1.3 [1.1-1.4]
 1 ICU-day(s) 57 (2.9) 196 (4.2) 1 43 (3.0) 209 (4.0) 1
No ICU-day 1912 (97.1) 4478 (95.8) 0.7 [0.5-0.9] 1377 (97.0) 5024 (96.0) 0.7 [0.5-1.0]
N ¼ 260 N ¼ 6383 N ¼ 263 N ¼ 6380
Last month of life
 1 ED-contact 187 (71.9) 887 (13.9) 1 112 (42.6) 963 (15.1) 1
No ED-contact 73 (28.1) 5496 (86.1) 15.8 [12.0-20.9] 151 (57.4) 5417 (84.9) 4.2 [3.2-5.4]
 1 ICU-day(s) 13 (5.0) 115 (1.8) 1 8 (3.0) 121 (1.9) 1S
No ICU-day 247 (95.0) 6281 (98.4) 2.9 [1.6-5.2] 255 (97.0) 6259 (98.1) 2.7 [1.3-5.6]
Abbreviations: CI, confidence interval; ED, emergency department; ICU, intensive care unit; OR, odds ratio.
Bold face values – Level of significance p < 0.05.
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however, as more information regarding the treatment aims and
patient preferences would be required to make this determina-
tion. The association we found could reflect 2 nonexclusive
contrasting possibilities: Patients receiving chemotherapy may
end up in the ED/ICU more often than those who do not
receive chemotherapy/radiotherapy due to an increase in
complications, or their ED/ICU admission may lead to che-
motherapy treatments; for instance, if a palliative treatment
aim is determined after their admission. Studies have shown
conflicting and inconclusive results regarding (palliative)
chemotherapy22-24; however, regardless of the direction of
this association, our data suggest that high-intensity care
(whether chemotherapy or an ICU admission) is associated
with the patient receiving other highly intensive care. Med-
ical specialists should consider the intensity of these treat-
ments when discussing them with their patients. Bearing in
mind that 80% of patients would prefer to die at home25,26
but only 61% actually do,26 we must ask whether this trend
is acceptable.
Although they are important for the initial staging process
of the cancer with acceptable cost-effectiveness parameters
and even cost savings,27 a CT scan might be unnecessary if it
will not make a difference to the subsequent treatment.
Schnipper et al even stated that “until high-level evidence
demonstrates that routine surveillance with PET or PET/CT
scans helps prolong life or promote wellbeing after treatment
for a specific type of cancer, this practice should not be
performed.”28(p4365) Given this recommendation, it is
remarkable that an average of 1.6 CT scans were still per-
formed on almost 10% of patients in their final month of life
or an average of 0.6 times for almost 30% of patients during
their final 3 months.
Strengths and Limitations
Amajor strength of our study was the analysis of the data at the
level of health-care activities. Although our database only
included hospital data, the use of these data enabled us to
analyze HCU in detail. Furthermore, the involvement of a
panel of medical experts enabled us to gather specialized input
and opinions and subsequently understand and interpret the
results. Our data were shown to be representative, as the mean
age at death and the male–female ratio for both cancer types
were comparable to the national mortality data.1
Our study also had some limitations, such as the fact that we
were not able to distinguish between curative and palliative
treatments in these data. This is important, as it would give
more insight into possible explanations for the HCU we have
found in our study. Also, registered health care does not always
necessarily reflect the actual health care supplied; faulty regis-
trations or nonregistrations do occur. Furthermore, the 2015
database was not complete at the time of this study due to the
time-consuming process of collecting data from Dutch hospi-
tals. When comparing the data from each year, however, we
found that our results were robust. We therefore argue that the
incompleteness of the data did not substantially alter the image
of the HCUP.
Although high-intensity hospital care is given to patients in
the EoL phase, some patients received no hospital-based care.
We were unable to investigate the differences in characteristics
and HCU between these 2 groups, but we believe that the
hospital-based patients are most likely to receive high-
intensity and high-cost, maybe even inappropriate, care during
the EoL phase in comparison to the nonhospital-based patients.
We do not know whether the care for nonhospital-based
patients was more appropriate than the hospital care provided
to other patients. In order to further investigate this, any geo-
graphical or institutional variations in HCU within the Nether-
lands need to be identified, as these are even stronger
indications of potential overuse and underuse. We also need
to broaden the scope of future studies by analyzing the full
health-care chain to determine which types of primary care
were provided for patients with high levels of secondary care
utilization and to identify the underlying reasons for differ-
ences in HCU. The ultimate aim would be to signal the overuse
and underuse of health care while also understanding it, leading
to better conversations between physicians/institutions and
patients to improve quality of care.
In conclusion, we observed a high usage of intense care in
the EoL phase of patients with CRC and LC in the Netherlands,
which may represent the overuse of health care, especially
regarding hospital admissions and CT scans. Palliative care
needs to be further improved and developed in the EoL phase
and may currently be underused. Advanced care planning can
play a substantial role in ensuring the appropriate use of pal-
liative care. More research is necessary to identify the true
overuse and underuse of hospital medical services.
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